bioAffinity Technologies, Inc. (BIAF) Current Ratio
- Current ratio · latest quarter: Value 1.44×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.44× | Current assets / current liabilities. $3.87M ÷ $2.68M ≈ 1.44× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 3.87M USD | Assets, Current |
| Current obligations | 2.68M USD | Liabilities, Current |
| Cash and equivalents | 2.43M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | 82.38K USD | Inventory, Net |
| Payables | 969.85K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.87M | $2.68M | $2.43M | (m) | (m) | $82.38K | $969.85K | (m) | 1.44× |
| 2026-03-31 | $4.34M | $3.18M | $3.10M | (m) | (m) | $77.89K | $836.21K | (m) | 1.36× |
| 2025-12-31 | $7.57M | $2.91M | $6.45M | (m) | (m) | $53.55K | $761.90K | (m) | 2.60× |
| 2025-09-30 | $8.61M | $2.36M | $7.67M | (m) | (m) | $35.23K | $940.76K | (m) | 3.65× |
| 2025-06-30 | $1.67M | $2.59M | $802.84K | (m) | (m) | $43.97K | $1.17M | (m) | 0.64× |
| 2025-03-31 | $1.86M | $3.42M | $444.71K | (m) | (m) | $38.78K | $1.38M | (m) | 0.55× |
| 2024-12-31 | $2.70M | $3.10M | $1.11M | (m) | (m) | $27.61K | $987.31K | (m) | 0.87× |
| 2024-09-30 | $2.55M | $2.49M | $756.58K | (m) | (m) | $25.36K | $782.94K | (m) | 1.02× |
| 2024-06-30 | $2.68M | $2.33M | $801.31K | (m) | (m) | $29.77K | $848.10K | (m) | 1.15× |
| 2024-03-31 | $3.93M | $1.77M | $2.45M | (m) | (m) | $9.49K | $383.99K | (m) | 2.22× |
| 2023-12-31 | $3.97M | $2.25M | $2.82M | (m) | (m) | $18.48K | $604.79K | (m) | 1.77× |
| 2023-09-30 | $6.01M | $1.96M | $4.51M | (m) | (m) | $9.91K | $827.41K | (m) | 3.07× |
| 2023-06-30 | $8.66M | $775.15K | $8.28M | (m) | (m) | $10.10K | $174.40K | (m) | 11.17× |
| 2023-03-31 | $10.23M | $796.30K | $9.77M | (m) | (m) | $11.34K | $146.54K | (m) | 12.85× |
| 2022-12-31 | $11.96M | $1.14M | $11.41M | (m) | (m) | $5.54K | $345.04K | (m) | 10.50× |
| 2022-09-30 | $14.05M | $1.46M | $13.50M | (m) | (m) | $5.71K | $149.87K | (m) | 9.60× |
| 2021-12-31 | $1.44M | $13.04M | $1.36M | (m) | (m) | (m) | $230.41K | (m) | 0.11× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |